NCT03746535CompletedEarly phase 1
Cardiovascular Disease Risk in Women With Endometriosis
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 17 Oct 2018
- Start date
- 1 Jul 2022
- Primary completion date
- 27 May 2025
- Lead sponsor
- Yale University
- Diseases
- Endometriosis
- NCT number
- NCT03746535
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 21
- From 1 Jul 2022 to the primary completion date, 27 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects who have diabetes,
Other
- Subjects who smoke
- Subjects with sleep apnea or BP\>140/90 will be excluded.
- Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
Who the study is looking for
- Young women between the ages of 18 and 45 years (Controls);
- Young women between the ages of 18 and 45 years with endometriosis.
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale School of Medicine Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.